{"id":"statin-ezetimibe-nutraceuticals","safety":{"commonSideEffects":[{"rate":null,"effect":"Myalgia or muscle pain"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Rhabdomyolysis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Statins inhibit HMG-CoA reductase to decrease endogenous cholesterol production in the liver. Ezetimibe blocks the Niemann-Pick C1-like 1 (NPC1L1) transporter to reduce dietary cholesterol absorption in the intestine. Nutraceuticals (such as plant sterols, red yeast rice, or polyphenols) provide complementary mechanisms to further reduce cholesterol levels and improve cardiovascular risk profiles.","oneSentence":"This combination reduces LDL cholesterol through dual inhibition of hepatic cholesterol synthesis (statin) and intestinal cholesterol absorption (ezetimibe), supplemented by nutraceuticals with additional lipid-modulating properties.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:09:41.872Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia management"},{"name":"Cardiovascular risk reduction in patients requiring intensive lipid lowering"}]},"trialDetails":[{"nctId":"NCT03277079","phase":"PHASE4","title":"Low Dose Statins, Ezetimibe and Nutraceuticals","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2017-10-01","conditions":"Coronary Artery Disease","enrollment":100},{"nctId":"NCT01807078","phase":"PHASE4","title":"Cholesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant Patients","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2014-01","conditions":"Coronary Artery Disease","enrollment":200},{"nctId":"NCT01490229","phase":"PHASE4","title":"Ezetimibe Versus Nutraceuticals in Statin-intolerant Patients","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2013-01","conditions":"Coronary Artery Disease","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Anticholesterol drug"],"phase":"marketed","status":"active","brandName":"statin + ezetimibe + Nutraceuticals","genericName":"statin + ezetimibe + Nutraceuticals","companyName":"University of Roma La Sapienza","companyId":"university-of-roma-la-sapienza","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces LDL cholesterol through dual inhibition of hepatic cholesterol synthesis (statin) and intestinal cholesterol absorption (ezetimibe), supplemented by nutraceuticals with additional lipid-modulating properties. Used for Hypercholesterolemia and dyslipidemia management, Cardiovascular risk reduction in patients requiring intensive lipid lowering.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}